Table 3.
DTH responses (diameter mm) before and during vaccine administration
| Group 1 patients treated with DCs + lysates ± IL-2 | Group 2 patients treated with DCs + peptides ± IL-2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient no. | Response (vaccines given)a | KLH | Lysate | Patient no. | Response (vaccines given)a | KLH | MART-1 | NA17 | Flu |
| ±IL-2 | ±IL-2 | ||||||||
| 1 | PD | 0, 25 | 0, 0 | 1 | SD | 0, 100 | 0, 26 | 0, 0 | 0, 0 |
| 2 | PD | 0, 21 | 0, 0 | 2 | PR | 0, 30 | 0, 30 | 0, 33 | 0, 300 |
| 3 | PD | 13, 6 | 0, 0 | 3 | SD | 0, 300 | 0, 150 | 0, 38 | 0, 200 |
| 4 | PD | 0, 28 | 0, 0 | 4 | PD (5) | 0, 0 | 0, 0 | 0, 0 | 0, 0 |
| 5 | PD (5) | 0, 29 (E) | 0, 09 | 5 | PD (4) | 0, Off study | |||
| 6 | PD (5) | 0, 0 | 0, 0 | 6 | PR | 10, 10 | 12, 12 | 0, 0 | 12, 16 |
| 7 | PD (4) | 0, Off study | 7 | PD (6) | 0, 10 (E) | 0, 10 | 0, 20 (E) | 0, 20 | |
| No IL-2 | 8 | SD | 2, 220 (E) | 2, 23 | 0, 5 | 3, 20 | |||
| 8 | SD | 0, 43 | 0, 0 | 9 | PD (5) | 0, 23 | 0, 0 | 0, 0 | 0, 0 |
| 9 | PD | 0, nd | 0, nd | No IL-2 | |||||
| 10 | SD | 0, 25 | 0, 0 | 10 | PD (2) | 0, Off study | |||
| 11 | PD (6) | 0, 25 | 0, 0 | 11 | PD | 0, 50 (E) | 0, 0 | 0, 0 | 0, 15 (E) |
| 12 | PD (6) | 0, 70 | 0, 0 | 12 | PD (5) | 0, 0 | 0, 0 | 0, 0 | 0, 0 |
| 13 | PD | 0, 50 | 0, 0 | 13 | PR | 0, 5 | 0, 5 | 0, 0 | 0, 5 |
| 14 | PD | 0, 0 | 0, 0 | 14 | PD | 0, 24 | 0, 17 | 0, 0 | 0, 20 |
| 15 | PD | 0, 35 | 0, 0 | 15 | SD | 0, 41 | 0, 10 | 0, 0 | 0, 25 |
| 16 | PD (3) | 0, nd | 0, nd | 16 | PD | 0, 25 | 0, 10 (E) | 0, 6 (E) | 0, 150 (E) |
| 17 | PD | 0, 0 | 0, 0 | 0, 0 | 0, 0 | ||||
| 18 | PD | 0, 130 | 0, 13 | 0, 0 | 2, 51 | ||||
There were no responses to gp100 280-9V, Tyrosinase or MAGE A-10 peptides
Patient 2 had a 3-mm indurated response to gp100 209 2M and patient 7 a 10-mm indurated response to MAGE3.A2
(E) indicates erythema but no induration
aAll patients had 7 vaccinations except where number in brackets are shown